KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other Non-Current Liabilities (2020 - 2026)

TherapeuticsMD filings provide 9 years of Other Non-Current Liabilities readings, the most recent being $873000.0 for Q1 2026.

  • On a quarterly basis, Other Non-Current Liabilities rose 9.81% to $873000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $873000.0, a 9.81% increase, with the full-year FY2025 number at $873000.0, up 17.34% from a year prior.
  • Other Non-Current Liabilities hit $873000.0 in Q1 2026 for TherapeuticsMD, roughly flat from $873000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $1.2 million in Q1 2022 to a low of $554000.0 in Q2 2022.
  • Median Other Non-Current Liabilities over the past 5 years was $832000.0 (2025), compared with a mean of $854764.7.
  • Biggest five-year swings in Other Non-Current Liabilities: plummeted 48.25% in 2022 and later soared 114.62% in 2023.
  • TherapeuticsMD's Other Non-Current Liabilities stood at $1.1 million in 2022, then tumbled by 42.55% to $636000.0 in 2023, then grew by 16.98% to $744000.0 in 2024, then rose by 17.34% to $873000.0 in 2025, then changed by 0.0% to $873000.0 in 2026.
  • The last three reported values for Other Non-Current Liabilities were $873000.0 (Q1 2026), $873000.0 (Q4 2025), and $871000.0 (Q3 2025) per Business Quant data.